BioVectra will manufacture the active pharmaceutical ingredient (API) for Phase II trials due to commence in Q2 next year and has agreed to invest C$1.5m (EUR939,349) in Texas-based Oncolix.
Dale Zajicek, BioVectra’s COO, said that: “Oncolix needed to identify a partner with a unique set of fermentation and downstream processing skills who was also willing to customize a scale-up plan, efficiently and effectively under the required regulations.”
Oncolix CEO Michael Redman explained that: “We chose BioVectra as our contract manufacturer because of their ability to produce cGMP manufacturing of Prolanta from shaker flask, to small-scale to full commercial production.”